Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on March 15, 2021. The registrant is a Delaware corporation with its principal executive offices in Farmington Hills, Michigan. The filing discloses material events related to the company's clinical trial progress.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a disclosure of non-financial corporate events.
Material Changes and Events
- Item 7.01 (Regulation FD Disclosure): The company posted an informational presentation on its website regarding the results of its MIRA-2 Phase 3 registration trial for the reversal of mydriasis.
- Item 8.01 (Other Events): The company issued a press release on March 15, 2021, announcing the same MIRA-2 Phase 3 trial results.
- Exhibits: The filing includes the investor presentation (Exhibit 99.1) and the press release (Exhibit 99.2) as attachments.
Guidance, Outlook, and Risks
The filing text itself does not provide specific numerical guidance, detailed management commentary, or a list of risks. It serves solely to reference the attached exhibits containing the trial results. The text explicitly states that the information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of the Securities Act or Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the specific statistical outcomes and primary endpoint results of the MIRA-2 Phase 3 trial by reviewing Exhibit 99.1 (Investor Presentation) and Exhibit 99.2 (Press Release) attached to this filing.
- Confirm the regulatory implications of the MIRA-2 results for the reversal of mydriasis.
- Note that the filing references Ocuphire Pharma, Inc. (Ticker: OCUP), not Opus Genetics, Inc.